Title |
Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001
|
---|---|
Published in |
Gynecologic Oncology Research and Practice, July 2017
|
DOI | 10.1186/s40661-017-0047-8 |
Pubmed ID | |
Authors |
Brett Miles, Howard P. Safran, Bradley J. Monk |
Abstract |
Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacterial vector Listeria monocytogenes (Lm) activates innate and adaptive immune responses and is expected to offer immunologic advantages. Axalimogene filolisbac (AXAL or ADXS11-001) is a novel immunotherapeutic based on the live, irreversibly attenuated Lm fused to the nonhemolytic fragment of listeriolysin O (Lm-LLO) and secretes the Lm-LLO-HPV E7 fusion protein targeting HPV-positive tumors. Herein are reported the development and recent results of various clinical trials in patients with HPV-associated cervical, head and neck, and anal cancers. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 61 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 13% |
Student > Master | 8 | 13% |
Student > Ph. D. Student | 7 | 11% |
Student > Bachelor | 7 | 11% |
Student > Postgraduate | 4 | 7% |
Other | 10 | 16% |
Unknown | 17 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 26% |
Biochemistry, Genetics and Molecular Biology | 11 | 18% |
Immunology and Microbiology | 7 | 11% |
Agricultural and Biological Sciences | 2 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 5 | 8% |
Unknown | 18 | 30% |